B-cell precursor acute lymphoblastic leukaemia
Haematology · 2019–2019
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| blinatumomab Treatment of patients with B-cell precursor acute lymphoblastic leukaemia (B-ALL) in haematological complete remission with minimal residual disease (MRD)… | Jul 2019 | Recommended with restriction | none received |
What the PBS pays
$33M in government benefit over 2024–25, across 458 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| blinatumomab | $33.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.